[
  {
    "ts": "2026-01-08T01:33:55+00:00",
    "headline": "Dow Jones Futures: Market Fades Off Highs; Eli Lilly Breaks Out, Google Trumps Apple",
    "summary": "The S&P 500 and Dow reversed from highs Wednesday, while the Nasdaq pared gains. Eli Lilly and Google flashed buy signals.",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-eli-lilly-google/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "e2c9a6ff-f5c0-3b9c-9e43-6b72385400a4",
      "content": {
        "id": "e2c9a6ff-f5c0-3b9c-9e43-6b72385400a4",
        "contentType": "STORY",
        "title": "Dow Jones Futures: Market Fades Off Highs; Eli Lilly Breaks Out, Google Trumps Apple",
        "description": "",
        "summary": "The S&P 500 and Dow reversed from highs Wednesday, while the Nasdaq pared gains. Eli Lilly and Google flashed buy signals.",
        "pubDate": "2026-01-08T01:33:55Z",
        "displayTime": "2026-01-08T01:33:55Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/e2c9a6ff-f5c0-3b9c-9e43-6b72385400a4/dow-jones-futures-market.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/9ce1a96c65f43cb2567d90f94b20e497",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5s9TlrXEGvo6f2yjWr3QjA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/9ce1a96c65f43cb2567d90f94b20e497.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5qXshpN1oJujuxnkmYfGOw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/9ce1a96c65f43cb2567d90f94b20e497.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-eli-lilly-google/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LMT"
            },
            {
              "symbol": "IDXX"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "LGND"
            },
            {
              "symbol": "LGNXZ"
            },
            {
              "symbol": "LGNYZ"
            },
            {
              "symbol": "LGNZZ"
            },
            {
              "symbol": "GOOG"
            },
            {
              "symbol": "IONS"
            },
            {
              "symbol": "BEIGF"
            },
            {
              "symbol": "ONC"
            },
            {
              "symbol": "BE"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "AAPL"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "GMED"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T03:21:48+00:00",
    "headline": "Dow Jones Futures Fall; Eli Lilly Breaks Out, Google Trumps Apple",
    "summary": "The S&P 500 and Dow reversed from highs Wednesday, while the Nasdaq pared gains. Eli Lilly and Google flashed buy signals.",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-eli-lilly-google/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "e2c9a6ff-f5c0-3b9c-9e43-6b72385400a4",
      "content": {
        "id": "e2c9a6ff-f5c0-3b9c-9e43-6b72385400a4",
        "contentType": "STORY",
        "title": "Dow Jones Futures Fall; Eli Lilly Breaks Out, Google Trumps Apple",
        "description": "",
        "summary": "The S&P 500 and Dow reversed from highs Wednesday, while the Nasdaq pared gains. Eli Lilly and Google flashed buy signals.",
        "pubDate": "2026-01-08T03:21:48Z",
        "displayTime": "2026-01-08T03:21:48Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/e2c9a6ff-f5c0-3b9c-9e43-6b72385400a4/dow-jones-futures-fall-eli.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/9ce1a96c65f43cb2567d90f94b20e497",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5s9TlrXEGvo6f2yjWr3QjA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/9ce1a96c65f43cb2567d90f94b20e497.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5qXshpN1oJujuxnkmYfGOw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/9ce1a96c65f43cb2567d90f94b20e497.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-eli-lilly-google/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LMT"
            },
            {
              "symbol": "LGND"
            },
            {
              "symbol": "LGNXZ"
            },
            {
              "symbol": "LGNYZ"
            },
            {
              "symbol": "LGNZZ"
            },
            {
              "symbol": "IDXX"
            },
            {
              "symbol": "BEIGF"
            },
            {
              "symbol": "ONC"
            },
            {
              "symbol": "GOOG"
            },
            {
              "symbol": "IONS"
            },
            {
              "symbol": "BE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "AAPL"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "GMED"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T11:03:32+00:00",
    "headline": "Analysis-Drugmakers brace for Europe pricing fight after Trump's US price-cut deals",
    "summary": "By Michael Erman and Maggie Fick NEW YORK/LONDON, Jan 8 (Reuters) - Global drugmakers face a battle in 2026 to secure higher prices for their prescription medicines in Europe after agreeing to cut U.S",
    "url": "https://finance.yahoo.com/news/analysis-drugmakers-brace-europe-pricing-110332596.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "d129a971-9e32-3d66-98c6-ed35a4fefb40",
      "content": {
        "id": "d129a971-9e32-3d66-98c6-ed35a4fefb40",
        "contentType": "STORY",
        "title": "Analysis-Drugmakers brace for Europe pricing fight after Trump's US price-cut deals",
        "description": "",
        "summary": "By Michael Erman and Maggie Fick NEW YORK/LONDON, Jan 8 (Reuters) - Global drugmakers face a battle in 2026 to secure higher prices for their prescription medicines in Europe after agreeing to cut U.S",
        "pubDate": "2026-01-08T11:03:32Z",
        "displayTime": "2026-01-08T11:03:32Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/4f6112ab97a43f073ae3d994866648b9",
          "originalWidth": 800,
          "originalHeight": 492,
          "caption": "FILE PHOTO: Euro banknotes and medicines are seen in this illustration taken, June 27, 2024. REUTERS/Dado Ruvic/Illustration/File Photo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A67BGnPqFqUYEGjkFMlYJA--~B/aD00OTI7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/4f6112ab97a43f073ae3d994866648b9.cf.webp",
              "width": 800,
              "height": 492,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o6ek8CTvZ3PFX1L.EC.mlQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/4f6112ab97a43f073ae3d994866648b9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/analysis-drugmakers-brace-europe-pricing-110332596.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/analysis-drugmakers-brace-europe-pricing-110332596.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AZN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T12:45:10+00:00",
    "headline": "Jim Cramer on Johnson & Johnson: “I Think It’s a Terrific Entry Point”",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer offered insights on. Cramer highlighted the company’s latest spin-off plans for one of its divisions, as he commented: “The fastest grower, the best opportunity here would not be Eli Lilly, which has moved a great deal and I still like, but Johnson & Johnson. […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-johnson-johnson-think-124510903.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "51ad0d83-8fd4-3d8c-b1c5-8787d41d2e96",
      "content": {
        "id": "51ad0d83-8fd4-3d8c-b1c5-8787d41d2e96",
        "contentType": "STORY",
        "title": "Jim Cramer on Johnson & Johnson: “I Think It’s a Terrific Entry Point”",
        "description": "",
        "summary": "Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer offered insights on. Cramer highlighted the company’s latest spin-off plans for one of its divisions, as he commented: “The fastest grower, the best opportunity here would not be Eli Lilly, which has moved a great deal and I still like, but Johnson & Johnson. […]",
        "pubDate": "2026-01-08T12:45:10Z",
        "displayTime": "2026-01-08T12:45:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/53474ea896ac24df22314d38ca381b1d",
          "originalWidth": 1920,
          "originalHeight": 1275,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/71v8XRd3wRmHgqQa9oQOkw--~B/aD0xMjc1O3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/53474ea896ac24df22314d38ca381b1d.cf.webp",
              "width": 1920,
              "height": 1275,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Nv41VbeJQNSmiwgo89Q4LQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/53474ea896ac24df22314d38ca381b1d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-johnson-johnson-think-124510903.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-johnson-johnson-think-124510903.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T12:39:22+00:00",
    "headline": "ANALYSIS-Drugmakers brace for Europe pricing fight after Trump's US price-cut deals",
    "summary": "NEW YORK/LONDON, Jan 8 (Reuters) - Global drugmakers face a battle in 2026 to secure higher prices for their prescription medicines in Europe after agreeing to cut U. pricing last year under pressure from President Donald Trump.",
    "url": "https://finance.yahoo.com/news/analysis-drugmakers-brace-europe-pricing-110332596.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "d129a971-9e32-3d66-98c6-ed35a4fefb40",
      "content": {
        "id": "d129a971-9e32-3d66-98c6-ed35a4fefb40",
        "contentType": "STORY",
        "title": "ANALYSIS-Drugmakers brace for Europe pricing fight after Trump's US price-cut deals",
        "description": "",
        "summary": "NEW YORK/LONDON, Jan 8 (Reuters) - Global drugmakers face a battle in 2026 to secure higher prices for their prescription medicines in Europe after agreeing to cut U. pricing last year under pressure from President Donald Trump.",
        "pubDate": "2026-01-08T12:39:22Z",
        "displayTime": "2026-01-08T12:39:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/1f7e367b692ce2ec1ab5356fa5b80aea",
          "originalWidth": 800,
          "originalHeight": 492,
          "caption": "FILE PHOTO: Euro banknotes and medicines are seen in this illustration taken, June 27, 2024. REUTERS/Dado Ruvic/Illustration/File Photo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bNJDwkbGko3GDUMJljspfA--~B/aD00OTI7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/1f7e367b692ce2ec1ab5356fa5b80aea.cf.webp",
              "width": 800,
              "height": 492,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5ciPVukwGMtL47VLxxMCVg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/1f7e367b692ce2ec1ab5356fa5b80aea.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/analysis-drugmakers-brace-europe-pricing-110332596.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/analysis-drugmakers-brace-europe-pricing-110332596.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AZN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T12:38:45+00:00",
    "headline": "Dow Jones Futures Fall; Lockheed, Defense Giants Bounce On $1.5 Trillion Trump 'Dream Military'",
    "summary": "Futures fell. Lockheed Martin and other defense giants jumped on Trump's proposed $1.5 trillion \"Dream Military\" budget.",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-lockheed-martin-trump-1-5-trillion-defense-budget/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "e2c9a6ff-f5c0-3b9c-9e43-6b72385400a4",
      "content": {
        "id": "e2c9a6ff-f5c0-3b9c-9e43-6b72385400a4",
        "contentType": "STORY",
        "title": "Dow Jones Futures Fall; Lockheed, Defense Giants Bounce On $1.5 Trillion Trump 'Dream Military'",
        "description": "",
        "summary": "Futures fell. Lockheed Martin and other defense giants jumped on Trump's proposed $1.5 trillion \"Dream Military\" budget.",
        "pubDate": "2026-01-08T12:38:45Z",
        "displayTime": "2026-01-08T12:38:45Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/e2c9a6ff-f5c0-3b9c-9e43-6b72385400a4/dow-jones-futures-fall-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/33f938a5fc2cb48ee7475fbefe5c2717",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DRV3rwpB_aSNHoX2xfxKbQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/33f938a5fc2cb48ee7475fbefe5c2717.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IbleJpX5C71_G6jvkD_iqw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/33f938a5fc2cb48ee7475fbefe5c2717.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-lockheed-martin-trump-1-5-trillion-defense-budget/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LMT"
            },
            {
              "symbol": "BEIGF"
            },
            {
              "symbol": "ONC"
            },
            {
              "symbol": "IDXX"
            },
            {
              "symbol": "IONS"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "GOOG"
            },
            {
              "symbol": "BE"
            },
            {
              "symbol": "LGND"
            },
            {
              "symbol": "LGNXZ"
            },
            {
              "symbol": "LGNYZ"
            },
            {
              "symbol": "LGNZZ"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "NOC"
            },
            {
              "symbol": "AAPL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T12:04:46+00:00",
    "headline": "Eli Lilly acquires inflammatory specialist Ventyx for $1.2bn",
    "summary": "The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.",
    "url": "https://www.pharmaceutical-technology.com/news/eli-lilly-acquires-inflammatory-specialist-ventyx-for-1-2bn/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "e2d2b4ad-e4e1-34bd-99dd-81182dcabc55",
      "content": {
        "id": "e2d2b4ad-e4e1-34bd-99dd-81182dcabc55",
        "contentType": "STORY",
        "title": "Eli Lilly acquires inflammatory specialist Ventyx for $1.2bn",
        "description": "",
        "summary": "The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.",
        "pubDate": "2026-01-08T12:04:46Z",
        "displayTime": "2026-01-08T12:04:46Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/d4027c66376f93a570dee16ff29420dd",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uAOCfDpCe4siW7.l9Q0Y9w--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/d4027c66376f93a570dee16ff29420dd.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/L8Eo12G3tGOLpcBxlegitQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/d4027c66376f93a570dee16ff29420dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/eli-lilly-acquires-inflammatory-specialist-ventyx-for-1-2bn/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-acquires-inflammatory-specialist-120446341.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTYX"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T11:45:34+00:00",
    "headline": "Eli Lilly in Advanced Talks to Buy Ventyx for About $1 Billion",
    "summary": "Sources say Lilly is discussing a $14-a-share cash deal for Ventyx, potentially announced as soon as Wednesday.",
    "url": "https://finance.yahoo.com/news/eli-lilly-advanced-talks-buy-114534873.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "76352787-7de3-3c1d-bf1a-c4080edbf9b3",
      "content": {
        "id": "76352787-7de3-3c1d-bf1a-c4080edbf9b3",
        "contentType": "STORY",
        "title": "Eli Lilly in Advanced Talks to Buy Ventyx for About $1 Billion",
        "description": "",
        "summary": "Sources say Lilly is discussing a $14-a-share cash deal for Ventyx, potentially announced as soon as Wednesday.",
        "pubDate": "2026-01-08T11:45:34Z",
        "displayTime": "2026-01-08T11:45:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/d0b2925021ba921981c34cbf188ac66c",
          "originalWidth": 500,
          "originalHeight": 500,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8b14zxH4BANQFraIfqB7ug--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/d0b2925021ba921981c34cbf188ac66c.cf.webp",
              "width": 500,
              "height": 500,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/j_oIKXponyFLhltsjvcwTQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/d0b2925021ba921981c34cbf188ac66c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-advanced-talks-buy-114534873.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-advanced-talks-buy-114534873.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTYX"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T09:45:00+00:00",
    "headline": "Best Growth Stocks to Buy for January 8th",
    "summary": "MU, LLY and SKIL made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 8th, 2026.",
    "url": "https://finance.yahoo.com/news/best-growth-stocks-buy-january-094500992.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "6658c371-7f98-35e0-9339-48adf3b41fd4",
      "content": {
        "id": "6658c371-7f98-35e0-9339-48adf3b41fd4",
        "contentType": "STORY",
        "title": "Best Growth Stocks to Buy for January 8th",
        "description": "",
        "summary": "MU, LLY and SKIL made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 8th, 2026.",
        "pubDate": "2026-01-08T09:45:00Z",
        "displayTime": "2026-01-08T09:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MjuR.4zEKm0FgKsxK.lBKQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G.VCDKzJSEg_sv.1sSAJrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/best-growth-stocks-buy-january-094500992.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/best-growth-stocks-buy-january-094500992.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MU"
            },
            {
              "symbol": "SKIL"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T13:16:51+00:00",
    "headline": "ClearBridge Large Cap Growth Strategy’s Thoughts on Eli Lilly and Company (LLY)",
    "summary": "ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” fourth-quarter 2025 investor letter. The investment philosophy of the strategy is to invest in leading companies that are undervalued by the market in terms of their future growth potential. A copy of the letter can be downloaded here. Large-cap stocks continued their […]",
    "url": "https://finance.yahoo.com/news/clearbridge-large-cap-growth-strategy-131651701.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "725ec4be-cdf4-3eb6-b348-5ad6cb346b9d",
      "content": {
        "id": "725ec4be-cdf4-3eb6-b348-5ad6cb346b9d",
        "contentType": "STORY",
        "title": "ClearBridge Large Cap Growth Strategy’s Thoughts on Eli Lilly and Company (LLY)",
        "description": "",
        "summary": "ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” fourth-quarter 2025 investor letter. The investment philosophy of the strategy is to invest in leading companies that are undervalued by the market in terms of their future growth potential. A copy of the letter can be downloaded here. Large-cap stocks continued their […]",
        "pubDate": "2026-01-08T13:16:51Z",
        "displayTime": "2026-01-08T13:16:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/a9fb68fd7057548f7ce119cac6a87e1c",
          "originalWidth": 768,
          "originalHeight": 430,
          "caption": "Was Jim Cramer Right About Eli Lilly and Company (LLY)?",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DFQyzS.MgxX7FGup4wuuQQ--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/a9fb68fd7057548f7ce119cac6a87e1c.cf.webp",
              "width": 768,
              "height": 430,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Lop4Pg7FGZ0GE4bKJLODDA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/a9fb68fd7057548f7ce119cac6a87e1c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/clearbridge-large-cap-growth-strategy-131651701.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/clearbridge-large-cap-growth-strategy-131651701.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T13:00:51+00:00",
    "headline": "Biotech Stocks' Dark Winter Is Over. What That Means For Investors.",
    "summary": "The long winter for biotech stocks is over.  Shares have climbed to levels not seen since late 2021, buoyed by eye-popping takeover valuations, trailblazing innovation in battling obesity and cancer, and a surprising, if uneasy, alliance with the Trump administration.  After peaking in February 2021, shares of Investor's Business Daily's Medical-Biomed/Biotech industry group plummeted more than 64% through April 2025.",
    "url": "https://www.investors.com/news/technology/biotech-stocks-2026-mergers-obesity-drugs/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "40ed1ed8-68dd-3a77-badd-6c086778df4d",
      "content": {
        "id": "40ed1ed8-68dd-3a77-badd-6c086778df4d",
        "contentType": "STORY",
        "title": "Biotech Stocks' Dark Winter Is Over. What That Means For Investors.",
        "description": "",
        "summary": "The long winter for biotech stocks is over.  Shares have climbed to levels not seen since late 2021, buoyed by eye-popping takeover valuations, trailblazing innovation in battling obesity and cancer, and a surprising, if uneasy, alliance with the Trump administration.  After peaking in February 2021, shares of Investor's Business Daily's Medical-Biomed/Biotech industry group plummeted more than 64% through April 2025.",
        "pubDate": "2026-01-08T13:00:51Z",
        "displayTime": "2026-01-08T13:00:51Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/40ed1ed8-68dd-3a77-badd-6c086778df4d/biotech-stocks-dark-winter.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/14fb694c11789929230c976b8b585e25",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SbPFxX5VW5dRGnbeROjGiQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/14fb694c11789929230c976b8b585e25.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KvZK7NFOZmoajf8lfHfhGQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/14fb694c11789929230c976b8b585e25.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/biotech-stocks-2026-mergers-obesity-drugs/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "ALNY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T13:00:00+00:00",
    "headline": "ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook",
    "summary": "Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; Phase 1 enrollment and dosing in healthy volunteers ongoing with target engagement data expected in H1 2026, followed by inclusion of a patient cohortDevelopment Candidates selected for pipeline programs AX-2402 for Rett syndrome (MECP2, R270X) and AX-2911 for MASH (PNPLA3)Strategic collaboration with Eli Lilly achieved $4.5 million in milestones in 2025, contributing to st",
    "url": "https://finance.yahoo.com/news/proqr-announces-encouraging-ax-0810-130000980.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "66ad403a-0968-33d8-8a0e-852e19af86cf",
      "content": {
        "id": "66ad403a-0968-33d8-8a0e-852e19af86cf",
        "contentType": "STORY",
        "title": "ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook",
        "description": "",
        "summary": "Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; Phase 1 enrollment and dosing in healthy volunteers ongoing with target engagement data expected in H1 2026, followed by inclusion of a patient cohortDevelopment Candidates selected for pipeline programs AX-2402 for Rett syndrome (MECP2, R270X) and AX-2911 for MASH (PNPLA3)Strategic collaboration with Eli Lilly achieved $4.5 million in milestones in 2025, contributing to st",
        "pubDate": "2026-01-08T13:00:00Z",
        "displayTime": "2026-01-08T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/a8f3e7fec6a7ab1f6f5d1766c1a4adcd",
          "originalWidth": 150,
          "originalHeight": 150,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rj3zzugilX7Iv7OEJFBOtA--~B/aD0xNTA7dz0xNTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a8f3e7fec6a7ab1f6f5d1766c1a4adcd.cf.webp",
              "width": 150,
              "height": 150,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mWDEBeQkRHJ.y4Z6i205ZA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a8f3e7fec6a7ab1f6f5d1766c1a4adcd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/proqr-announces-encouraging-ax-0810-130000980.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/proqr-announces-encouraging-ax-0810-130000980.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PRQR"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T13:00:00+00:00",
    "headline": "Benchling and Lilly TuneLab Partner to Democratize Access to AI Models for Scientists Everywhere",
    "summary": "Benchling, the platform for scientific progress, today announced a strategic collaboration with Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform created by Eli Lilly and Company (Lilly) to provide access to models trained on decades of Lilly's proprietary research data, representing over $1 billion in research investment. Through this program, Lilly is extending TuneLab's reach to Benchling's customer base of more than 1,300 biotech companies. Scientists will be ab",
    "url": "https://finance.yahoo.com/news/benchling-lilly-tunelab-partner-democratize-130000425.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "16a2d066-8c1c-31f5-b192-37d72cd96d8c",
      "content": {
        "id": "16a2d066-8c1c-31f5-b192-37d72cd96d8c",
        "contentType": "STORY",
        "title": "Benchling and Lilly TuneLab Partner to Democratize Access to AI Models for Scientists Everywhere",
        "description": "",
        "summary": "Benchling, the platform for scientific progress, today announced a strategic collaboration with Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform created by Eli Lilly and Company (Lilly) to provide access to models trained on decades of Lilly's proprietary research data, representing over $1 billion in research investment. Through this program, Lilly is extending TuneLab's reach to Benchling's customer base of more than 1,300 biotech companies. Scientists will be ab",
        "pubDate": "2026-01-08T13:00:00Z",
        "displayTime": "2026-01-08T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/3ae362293b671df63c5faa3c801c95eb",
          "originalWidth": 400,
          "originalHeight": 225,
          "caption": "Collaboration makes AI models trained on over $1 billion in Lilly research data accessible directly in scientists' workflows in Benchling",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ihTdzPI8ockein39cCnsgw--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/3ae362293b671df63c5faa3c801c95eb.cf.webp",
              "width": 400,
              "height": 225,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2.ZYqOp9gE6ezFMMMt0.6g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/3ae362293b671df63c5faa3c801c95eb.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/benchling-lilly-tunelab-partner-democratize-130000425.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/benchling-lilly-tunelab-partner-democratize-130000425.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T15:13:34+00:00",
    "headline": "How Eli Lilly's Plan To Buy Ventyx For $1.2 Billion Could Benefit Neumora, Neurocrine",
    "summary": "Eli Lilly's plan to buy Ventyx for $1.2 billion benefits more than the takeover target, an analyst said Thursday.",
    "url": "https://www.investors.com/news/technology/eli-lilly-ventyx-biosciences-ventyx-stock/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "cb135bcc-842f-31ad-b0ec-a586910de970",
      "content": {
        "id": "cb135bcc-842f-31ad-b0ec-a586910de970",
        "contentType": "STORY",
        "title": "How Eli Lilly's Plan To Buy Ventyx For $1.2 Billion Could Benefit Neumora, Neurocrine",
        "description": "",
        "summary": "Eli Lilly's plan to buy Ventyx for $1.2 billion benefits more than the takeover target, an analyst said Thursday.",
        "pubDate": "2026-01-08T15:13:34Z",
        "displayTime": "2026-01-08T15:13:34Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/cb135bcc-842f-31ad-b0ec-a586910de970/how-eli-lilly-s-plan-to-buy.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/67464aa2598bc109a3cce706482c0735",
          "originalWidth": 1012,
          "originalHeight": 572,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/45lZaPmm8vZHt8t16Pv3Sw--~B/aD01NzI7dz0xMDEyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/67464aa2598bc109a3cce706482c0735.cf.webp",
              "width": 1012,
              "height": 572,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zVkqSTYjINnOUb2UYhN_og--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/67464aa2598bc109a3cce706482c0735.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/eli-lilly-ventyx-biosciences-ventyx-stock/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTYX"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NBIX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T14:35:00+00:00",
    "headline": "Is LLY's Ventyx Deal Another Attempt at Diversification Beyond GLP-1?",
    "summary": "Eli Lilly ramps up M&A activity, adding Ventyx and other assets to diversify beyond obesity as competition in the GLP-1 space intensifies.",
    "url": "https://finance.yahoo.com/news/llys-ventyx-deal-another-attempt-143500049.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "09a26933-b355-3b41-a79d-6cc9a9316799",
      "content": {
        "id": "09a26933-b355-3b41-a79d-6cc9a9316799",
        "contentType": "STORY",
        "title": "Is LLY's Ventyx Deal Another Attempt at Diversification Beyond GLP-1?",
        "description": "",
        "summary": "Eli Lilly ramps up M&A activity, adding Ventyx and other assets to diversify beyond obesity as competition in the GLP-1 space intensifies.",
        "pubDate": "2026-01-08T14:35:00Z",
        "displayTime": "2026-01-08T14:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/3c8c5ffebabb5a0d6f7bffb8eb41c523",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Zg3ykhh14An2bfVuUvzbag--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3c8c5ffebabb5a0d6f7bffb8eb41c523.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8KeSNQWO2yQtdmAEk3F_Nw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3c8c5ffebabb5a0d6f7bffb8eb41c523.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/llys-ventyx-deal-another-attempt-143500049.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/llys-ventyx-deal-another-attempt-143500049.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-08T14:11:00+00:00",
    "headline": "RVMD Stock Hits a Record High on Rumored Takeover Interest",
    "summary": "Revolution Medicines shares jump nearly 29% to a record high after a WSJ report said AbbVie showed takeover interest, a claim the pharma giant later denied.",
    "url": "https://finance.yahoo.com/news/rvmd-stock-hits-record-high-141100306.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "bc0383dc-8d9f-33cc-ad64-5c4fae1e9d9e",
      "content": {
        "id": "bc0383dc-8d9f-33cc-ad64-5c4fae1e9d9e",
        "contentType": "STORY",
        "title": "RVMD Stock Hits a Record High on Rumored Takeover Interest",
        "description": "",
        "summary": "Revolution Medicines shares jump nearly 29% to a record high after a WSJ report said AbbVie showed takeover interest, a claim the pharma giant later denied.",
        "pubDate": "2026-01-08T14:11:00Z",
        "displayTime": "2026-01-08T14:11:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TNBAnrhWOnvvvNSvMEIuFg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rP7ZEHNft_Sb_FB9M.3i3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/rvmd-stock-hits-record-high-141100306.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/rvmd-stock-hits-record-high-141100306.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "RVMD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]